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Background: Social anxiety is among the most prevalent and debilitating affective disturbances manifest in people
with psychosis. It is usually accompanied by high levels of depression and leads to significant social disability, lower
quality of life and poorer prognosis as it raises the possibility of an early relapse. Despite its elevated prevalence
and severity in psychosis, social anxiety remains under-recognized and under-treated. Cognitive-behavioural therapy
is recommended for the treatment of people with psychosis. However, its focus and evaluation has primarily revolved
around the reduction of psychotic symptoms, and not for co-morbid affective disturbances such as social anxiety. There
is lack of evidence on the clinical effectiveness and cost-effectiveness of cognitive-behavioural interventions for the
treatment of social anxiety disorder in psychosis.
Methods/Design: Electronic databases will be systematically searched for randomised controlled trials and
quasi-experimental studies investigating the effectiveness and cost-effectiveness of cognitive-behavioural interventions
for the treatment of social anxiety disorder in people with psychosis. Grey literature will also be searched by screening
trial registers. Only studies published in English will be included in the review. Date restrictions will not be applied.
Eligible studies will have as the primary outcome social anxiety (continuous data) measured using any psychometrically
validated scale both self-reported and clinician administered. Secondary outcomes will include general anxiety
symptoms, distress, depression, positive and negative symptoms of schizophrenia, and quality of life measured using
any psychometrically validated scale, both self-reported and clinician administered, and the cost of cognitive-behaviour
therapy (CBT) intervention (with another treatment or treatment-as-usual).
Conclusions: This review will provide an evidence synthesis of the effectiveness and cost-effectiveness of
cognitive-behavioural interventions for the treatment of social anxiety disorder in people with psychosis. The review
will identify the specific intervention components associated with effectiveness which will facilitate the translation of
the existing evidence to the development of new, targeted interventions optimising these components. In doing so,
this review will provide recommendations for the treatment of social anxiety and associated distress in psychosis and
will further inform the development of future interventions in this area.
Trial registration: PROSPERO registration number CRD42014009052.
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Social anxiety disorder is among the most frequently re-
ported psychiatric disorders with a lifetime prevalence of
12% and a 12-month prevalence of 7.1% [1]. According
to the Diagnostic and Statistical Manual of Mental Dis-
orders, Fifth Edition (DSM-5) [2], social anxiety dis-
order (previously known as social phobia) is defined
as “a marked fear or anxiety about one or more social
situations in which the individual is exposed to possible
scrutiny by others. Examples include social interactions
(e.g., having a conversation), being observed (e.g., eat-
ing or drinking), or performing in front of others (e.g.,
giving a speech).”
People with social anxiety desire to make a favourable
impression during social encounters but at the same
time doubt their ability to do so; they fear that they will
be scrutinized and negatively evaluated due to perceived
failed social performance. These fears lead people with
social anxiety to avoid all or some social situations and
in extreme cases this could lead to complete social isola-
tion [3]. Exposure to the feared situation is almost al-
ways accompanied by physical symptoms, for example,
sweating, trembling, heart racing, which could develop
(although not necessarily) into panic attacks.
Social anxiety develops at an early age, usually during
childhood or adolescence and, once established, follows
a stable, chronic course if treatment is not initiated
([4,5]; Findings regarding the sociodemographic charac-
teristics of social anxiety disorder support that this is
more prominent among females [6-10] although there
have been studies [11] which have failed to confirm such
gender differences. Higher incident rates have been con-
sistently observed among unmarried individuals usually
coming from a lower socioeconomic background, with
poorer educational attainment and higher unemploy-
ment rates [6,7,10]. The average duration of illness is ap-
proximately 29 years [4,12] and the likelihood of a full
remission or recovery is significantly lower compared to
that of other anxiety disorders [12].
Social anxiety disorder in psychosis
Social anxiety is among the most prevalent and de-
bilitating affective disturbances manifested in people
with psychosis with rates ranging between 8% and 36%
([13-15]; [16,17]; [18,19]). Social anxiety is usually accom-
panied by high levels of depression ([19];) and leads to
significant social disability [17], a reduced quality of life
[16] and poorer prognosis as it raises the possibility of
an early relapse [20]. Despite its elevated prevalence
and severity in psychosis, social anxiety remains under-
recognized and under-treated. One of the reasons for
this could be that the exact relationship between social
anxiety and psychotic symptoms is yet to be determined
and available empirical findings remain inconclusive [21].Although theoretical models and empirical evidence con-
sistently point towards a link between general anxiety and
positive symptoms of psychosis, predominantly paranoia
and persecutory delusions [22], social anxiety appears to
have a distinct quality and its relationship to paranoia and
persecutory thinking is not straightforward. Four path-
ways have been proposed for the understanding of the on-
togeny of social anxiety in psychosis [19,23]:
1. Social anxiety predates the onset of paranoia and
helps maintain persecutory beliefs
2. Social anxiety and paranoia develop concurrently
in the early phase of psychosis and follow a
similar course
3. Social anxiety develops as a consequence of paranoid
beliefs
4. Social anxiety emerges as a response to the shame
and social stigma attached to a diagnosis of mental
illness
Clinical implications
Cognitive-behavioural therapy (CBT) is recommended
by the National Institute for Health and Care Excellence
[24] for people with psychosis. However, the focus and
evaluation of CBT for psychosis has primarily revolved
around the reduction of psychotic symptoms, and not
for co-morbid depression and social anxiety [23,25]. There
is lack of evidence on the clinical effectiveness and cost
effectiveness of CBT interventions for the treatment of
affective dysregulation and associated distress in psychosis
and particularly so for social anxiety disorder.
Aim
This systematic review and meta-analysis will provide
an evidence synthesis of the effectiveness and cost-
effectiveness of CBT interventions for the treatment of
social anxiety disorder in people with psychosis. In doing
so, this review will provide recommendations for the
treatment of social anxiety and associated distress in
psychosis and will further inform the development of fu-
ture interventions in this area. To the best of the authors’
knowledge this is the first systematic review of CBT in-
terventions for social anxiety in psychosis.
Objectives
Our objectives are:
1. To synthesize the evidence of the effectiveness and
cost-effectiveness of CBT interventions for the
treatment of social anxiety disorder in people
with psychosis in improving outcomes related to
social anxiety symptoms, general anxiety, distress,
depression, positive and negative symptoms of
schizophrenia, and quality of life.
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interventions for the treatment of social anxiety
disorder in people with psychosis in improving
outcomes related to social anxiety symptoms,
general anxiety, distress, depression, positive and
negative symptoms of schizophrenia, and quality
of life.Methods/Design
Study design
We shall conduct a systematic review and meta-analysis
and we will report the outcomes according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [26] following the
guidelines in the Cochrane Handbook for Systematic
Reviews of Interventions [27].Search strategy
The literature search strategy is included in Additional
file 1. The following search limits will be set: 1) Study
design: randomised controlled trials (RCTs) and quasi-
experimental studies, 2) limited to English language.
Date restrictions will not be applied. The following bib-
liographic databases will be searched:
▪ Cochrane Central Register of Controlled Trials





▪ SCI (Science Citation Index)
Grey literature
▪ Clinical Trials: clinicaltrials.gov
▪ ISRCTN Register
Search terms
We shall use Medical Subject Headings (MeSH) and
free-text word terms, as appropriate to the databases.










Treatment efficacySearch strategies will be pilot tested. We shall use




Participants will be between 16 and 65 years of age, with
schizophrenia or related psychoses (as diagnosed using
any recognized diagnostic criteria) with social anxiety
disorder as diagnosed using any recognised diagnostic
criteria, for example, ICD-10 [28] or DSM-5 [2]. Studies
including participants <16 yrs or >65 yrs or participants
with a primary diagnosis of organic brain disorder will
be excluded from this review.
Types of studies
RCTs and quasi-experimental studies will be included in
the review.
Types of intervention
The review will include cognitive-behavioural (or
cognitive) interventions that are targeted at social anxiety
in people with psychosis. There will be no limitation in
terms of psychological theory informing the intervention,
the person delivering the intervention or the setting in
which the intervention is delivered. Group and one-to-
one interventions will be included.
Comparator
Control conditions will include any other treatment, no
treatment, treatment-as-usual and a waiting list control.
Types of outcomes
Primary outcome
Eligible studies will have as primary outcome social anx-
iety (continuous data) measured using any psychomet-
rically validated scale, both self-reported and clinician
administered.
Secondary outcomes
These will include general anxiety symptoms, distress,
depression, positive and negative symptoms of schizo-
phrenia and quality of life measured using any psycho-
metrically validated scale both self-reported and clinician
administered, and the cost of CBT intervention (with an-
other treatment or treatment-as-usual).
Selection procedure
Two researchers (MM and LT) will independently screen
the title and abstract of retrieved references for inclu-
sion. The full text of all potential eligible studies will be
obtained by MM. The next step will involve two re-
searchers (MM and LT) independently assessing ob-
tained references for inclusion. We shall pilot test the
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ments will be resolved by consensus.
Managing references
Bibliographic software (EndNote) (Thomson Reuters),
will be used to manage retrieved references. MM will be
responsible for identifying and removing duplicates, or-
dering and recording the receipt of any inter-library
loans and obtaining the full-text papers. MM will be the
sole team member responsible for adding or amending
library records in EndNote.
Data extraction, procedures and data management
The EPOC data extraction form in combination with the
EPOC data checklist (see Additional file 2) will be used
to extract data from relevant studies. Two reviewers
(MM and LT) will work independently to extract data.
Disagreements between the two reviewers will be re-
solved by discussion and consensus, or resolved by a
third author (MB). Data extraction will include study
setting, study population and participant demographics
and baseline characteristics, details of the intervention
and control conditions, study methodology, recruit-
ment and study completion rates, outcomes and times
of measurement, indicators of acceptability to users,
suggested mechanisms of intervention action, informa-
tion for assessment of the risk of bias and variables re-
lated to study quality. Study authors will be contacted
to request data missing on methods or results. Informa-
tion on missing data and dropouts will be assessed for
each study. We will report the number of participants
included in the final analysis of each study as a pro-
portion of all participants in the study. The possible
effects of the missing data will be discussed. Data will
be included only for those participants whose results
are known.
Dealing with missing data
Study authors will be contacted to request data missing
on methods or results. Information on missing data and
dropouts will be assessed for each study. We will report
the number of participants included in the final analysis
of each study as a proportion of all participants in the
study. The possible effects of the missing data will be
discussed. Data will be included only for those partici-
pants whose results are known.
Quality assessment
We shall assess the quality of studies and assessment of
bias using the Cochrane’s Collaboration tool for asses-
sing risk of bias presented in Additional file 3 [29]. Two
researchers (MM and LT) will independently rate risk of
bias of each study. Discrepancies will be resolved by dis-
cussion and consensus.Data analysis
Measures of treatment effects
We shall summarise and describe the characteristics
of the population, interventions and outcomes, using
descriptive statistics. Standardised mean differences,
Hedges g, and weighting studies using inverse of variance
will be calculated for continuous outcomes. Risk ratios
(RR) will be calculated and we shall use the Mantel-
Haenszel method to combine studies. We shall report
outcomes using 95% confidence intervals (CI), with
random-effects models.
Assessment of reporting biases
Funnel plots will be drawn to investigate the relationship
between study power and effect size. Possible reasons
for any asymmetry will be discussed.
Data synthesis and assessment of heterogeneity
A meta-analysis of RCTs and quasi-experimental studies
will be conducted using RevMan.
Statistical tests of heterogeneity (chi-square and I-
square) will be carried out. A random-effects model will
be used to allow for expected heterogeneity. Effect esti-
mates will be weighted by the inverse of their variance,
giving greater weight to larger trials.
Sub group analyses will be carried out for studies with
similar research questions based on: a) type of interven-
tions: group-based CBT; individual CBT and b) phase of
illness: early onset psychosis vs. chronic.
Sensitivity analysis will be carried out to explore
the effects of the addition or removal of lower quality
studies.
We will use the GRADE system 11 [30] to assess con-
fidence in the quality of evidence of individual outcomes
and strength of recommendations.
Discussion
CBT is recommended by the National Institute for
Health and Care Excellence [24] for people with psych-
osis. However, its focus and evaluation for psychosis has
primarily revolved around the reduction of psychotic
symptoms, and not for co-morbid depression and social
anxiety [23,25]. There is lack of evidence on the clinical
effectiveness and cost effectiveness of CBT interventions
for the treatment of affective dysregulation and associ-
ated distress in psychosis and particularly so for social
anxiety disorder. This review will therefore provide
an evidence synthesis of the effectiveness and cost-
effectiveness of CBT interventions for the treatment of
social anxiety disorder in people with psychosis. The re-
view will identify the specific intervention components
associated with effectiveness which will facilitate the
translation of the existing evidence to the development of
new, targeted interventions optimising these components.
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the treatment of social anxiety and associated distress in
psychosis and will further inform the development of fu-
ture interventions in this area. To the best of the authors’
knowledge, this is the first systematic review of CBT inter-
ventions for social anxiety in psychosis.
Additional files
Additional file 1: Literature search strategy template. The file
provides a description of the literature search strategy.
Additional file 2: Data abstraction form. Form that will be used by
the authors to extract data.
Additional file 3: Quality assessment tool. Tool that will be used by
the authors to assess risk of bias.
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